Established in 2017, AdvaGen Pharma is an integrated specialty pharmaceutical company, focused on providing innovative solutions for patients, customers, and partners by developing, manufacturing, and marketing high quality prescription branded and generic pharmaceutical products.
AdvaGen Pharma is poised for growth by introducing value-added pharmaceuticals across the oral solids, oral liquids, topicals, injectables, and nasal spray dosage forms, as well as niche, high barrier opportunities across medical devices and drug-device combinations. AdvaGen Pharma sources its products from its parent organization, Rubicon Research Pvt Ltd, as well as from a network of high quality, FDA inspected manufacturing facilities across the globe. AdvaGen’s strong focus on reliable supplies is backed by own manufacturing across oral solid and liquid products and upcoming expansion of sites to also include complex dosage forms like sterile and drug device products. AdvaGen will continue to source over 70% of its products by in-house manufacturing through its rapid expansion portfolio expansion.
The name AdvaGen is a combination of the words ‘ADVAnced GENerics’ and we believe that we are firmly on our way to establishing our mission through our rapidly expanding product portfolio, innovations that fulfil unmet medical needs, and by enabling smarter health care delivery.
AdvaGen Pharma is headquartered in Plainsboro, New Jersey.
14 products available across 50 SKUs
10+ new launches slated for 2021
50 states distribution presence
Wholesaler and hospital channel sales
1.3 bn+ extended units distributed for approved products in 2020
About Our Parent Company Rubicon Research
Rubicon Research is an IP led, specialty pharmaceutical company focused on a mission to provide innovative yet affordable patient-centered products and solutions to address unmet needs around the world. We leverage our proprietary technologies and specialized formulation development skills to provide solutions to complex delivery challenges, enabling better patient outcomes.
Our portfolio spans multiple dosage forms, including oral solids, oral liquids, nasal, ophthalmic, injectable, topical, drug device combinations and fixed-dose combinations. We hold more than 50 issued patents in drug delivery technologies, and have launched over 40 SKUs, with over 1 billion extended units sold in the US. In the pipeline are 20 approvals and launches (across oral solids and ophthalmic formulations). Additionally, there are more than 70 products in development and 10+ filed products under review with the US FDA.
For more information visit www.rubicon.co.in